Tempus AI Stock-Based Compensation 2023-2025 | TEM

Tempus AI annual/quarterly stock-based compensation history and growth rate from 2023 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
  • Tempus AI stock-based compensation for the quarter ending June 30, 2025 was $0.045B, a 90.7% decline year-over-year.
  • Tempus AI stock-based compensation for the twelve months ending June 30, 2025 was $1.112B, a 127.7% increase year-over-year.
  • Tempus AI annual stock-based compensation for 2024 was $0.534B, a 0% decline from 2023.
  • Tempus AI annual stock-based compensation for 2023 was $0B, a 0% decline from 2022.
  • Tempus AI annual stock-based compensation for 2022 was $0B, a 0% decline from .
Tempus AI Annual Stock-Based Compensation
(Millions of US $)
2024 $534
2023 $N/A
2022 $N/A
Sector Industry Market Cap Revenue
Medical Medical Information Systems $12.722B $0.693B
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
Stock Name Country Market Cap PE Ratio
Veeva Systems (VEEV) United States $47.976B 58.72
Doximity (DOCS) United States $12.734B 56.66
Hims & Hers Health (HIMS) United States $9.947B 81.50
IRhythm Technologies (IRTC) United States $5.455B 0.00
Hinge Health (HNGE) United States $4.531B 0.00
Heartflow (HTFL) $2.821B 0.00
Inspire Medical Systems (INSP) United States $2.730B 40.13
Privia Health (PRVA) United States $2.669B 197.73
Phreesia (PHR) United States $1.904B 0.00
Enovis (ENOV) United States $1.773B 9.37
10x Genomics (TXG) United States $1.745B 0.00
Omnicell (OMCL) United States $1.526B 29.41
Schrodinger (SDGR) United States $1.457B 0.00
Azenta (AZTA) United States $1.384B 60.40
Clover Health Investments (CLOV) United States $1.379B 0.00
Claritev (CTEV) United States $1.184B 0.00
Evolent Health (EVH) United States $1.130B 0.00
Fulgent Genetics (FLGT) United States $0.662B 0.00
Zepp Health (ZEPP) Netherlands $0.542B 0.00
Veradigm (MDRX) United States $0.535B 0.00
Standard BioTools (LAB) United States $0.489B 0.00
Talkspace (TALK) United States $0.454B 135.50
Butterfly Network (BFLY) United States $0.395B 0.00
Carlsmed (CARL) United States $0.369B 0.00
TruBridge (TBRG) United States $0.302B 52.95
Health Catalyst (HCAT) United States $0.260B 0.00
Outset Medical (OM) United States $0.248B 0.00
SOPHiA GENETICS SA (SOPH) Switzerland $0.225B 0.00
Nyxoah SA (NYXH) Belgium $0.210B 0.00
KORU Medical Systems (KRMD) United States $0.197B 0.00
CapsoVision (CV) United States $0.185B 0.00
MDxHealth SA (MDXH) Belgium $0.170B 0.00
CareCloud (CCLD) United States $0.157B 7.13
ImmunoPrecise Antibodies (IPA) Canada $0.122B 0.00
American Well (AMWL) United States $0.112B 0.00
EUDA Health Holdings (EUDA) Singapore $0.085B 0.00
Pulmonx (LUNG) United States $0.076B 0.00
Insight Molecular Diagnostics (IMDX) United States $0.071B 0.00
111 (YI) China $0.061B 0.00
P3 Health Partners (PIII) United States $0.056B 0.00
HeartBeam (BEAT) United States $0.040B 0.00
Precipio (PRPO) United States $0.025B 0.00
Zhongchao (ZCMD) China $0.025B 0.00
Healthcare Triangle (HCTI) United States $0.015B 0.00
PROFUSA (PFSA) United States $0.013B 0.00
Bullfrog AI Holdings (BFRG) United States $0.013B 0.00
Predictive Oncology (POAI) United States $0.010B 0.00
Strata Skin Sciences (SSKN) United States $0.009B 0.00
HeartSciences (HSCS) United States $0.008B 0.00
Mobile-health Network Solutions (MNDR) Singapore $0.005B 0.00
MSP Recovery (MSPR) United States $0.004B 0.00
Movano (MOVE) United States $0.004B 0.00
Evaxion - (EVAX) Denmark $0.004B 0.00
Tivic Health Systems (TIVC) United States $0.003B 0.00